TY - JOUR
T1 - Efficacy and Safety of Talazoparib (TALA) or Physician's Choice of Therapy (PCT) in United States Patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) Locally Advanced/Metastatic Breast Cancer (LA/MBC) in the EMBRACA Study
AU - Mahtani, Reshma
N1 - 1044 Background: TALA is a poly(ADP-ribose) polymerase (PARP) inhibitor approved in the US for HER2- gBRCAm LA/MBC. Approval was based on results from the Phase 3 EMBRACA trial comparing efficacy/safety of TALA (1 mg/d) to PCT (capecitabine, eribulin, gemcitabine, vinorelbine) in HER2- gBRCAm LA/MBC pts.
PY - 2019
Y1 - 2019
N2 - Sami Diab , Hope S. Rugo , Lida A. Mina , Shannon Puhalla , Norah Lynn Henry , Neelima Denduluri , Denise A. Yardley , Yao Wang , Lillian Shahied Arruda , Iulia Cristina Tudor , Eric Roland Gauthier , Akos Gabor Czibere , Jennifer Keating Litton , Sara A. Hurvitz
AB - Sami Diab , Hope S. Rugo , Lida A. Mina , Shannon Puhalla , Norah Lynn Henry , Neelima Denduluri , Denise A. Yardley , Yao Wang , Lillian Shahied Arruda , Iulia Cristina Tudor , Eric Roland Gauthier , Akos Gabor Czibere , Jennifer Keating Litton , Sara A. Hurvitz
UR - https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.1044
M3 - Article
VL - 37
JO - Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting
JF - Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting
ER -